Opyl Limited (ASX:OPL) has announced a new agreement with Biointelect, a leading Clinical Research Organisation (CRO) and strategic planning and commercialisation advisory firm for the life science sector. The six-month agreement will involve Biointelect leveraging Opyl's TrialKey platform to provide advanced clinical trial design and predictive analytics at a fee of $5,000 per trial.
Saurabh Jain, Executive Chairman of Opyl, expressed excitement about the partnership with Biointelect, aiming to transform clinical trial designs and boost the probability of success for Biointelect's clients. Jacqui Wade, Director, Clinical Affairs & Director Services at Biointelect, highlighted the significant value that Opyl's TrialKey platform brings to their clients, emphasizing the critical role of data-driven insights in optimizing trial outcomes.
Opyl Limited's new agreement with Biointelect involves the utilization of TrialKey platform to provide advanced clinical trial design and predictive analytics. The collaboration aims to enhance Biointelect's clinical trial design capabilities and support more informed product development pathways. Looking ahead, Biointelect has already been awarded two projects, with Opyl set to collaborate on future proposals, ensuring TrialKey's advanced analytics are part of their upcoming clinical trial designs.